

# Chemical & Biological Profiling Approaches for exploring Mutagenicity & Carcinogenicity of EPA ToxCast Chemicals

EMS, St. Louis, MO, October 26, 2009

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY





**Ann Richard**  
richard.ann@epa.gov

# Change Needed Because .....

*Too Many Chemicals*


*Too High a Cost*



*...and not enough data.*


# ToxCast™ Background

- Goal to address chemical screening and prioritization needs for high priority EPA chemical inventories:
  - *pesticidal inerts, anti-microbials, CCLs, HPVs, MPVs*
- Coordinated with NTP and NIH/NCGC via Tox21
- Committed to stakeholder involvement and public release of data & tools
  - Communities of Practice- Chemical Prioritization & Exposure
  - NCCT website <http://www.epa.gov/ncct/toxcast>
    - ACToR <http://www.epa.gov/actor/>
    - ToxRef DB <http://www.epa.gov/ncct/toxrefdb/>
    - DSSTox (PubChem) <http://www.epa.gov/ncct/dsstox/>



**Cellular Assays**

**Biochem Assay**



# Biochemical Assays

**Chemical Structure & Properties**

QAP properties for 285 chemicals


Descriptors (Y-axis):

- XcHummAbs
- DiploDivVol
- IndexConcInMS
- FISA
- dipole
- logPw
- FISA
- FISA
- PMOCK
- WPSA
- Pkaco
- logHERG
- globularity
- logS
- ClogP
- IP\_EV
- EA\_EV
- logPb
- logBB
- FOSA
- logPns
- logPov
- MW
- SASA
- logPCT1
- logPCT6
- volume
- PolrZ

## Predict


**Toxicology Endpoints**

# ToxCast Phase I Chemicals



# Chemical Classes in ToxCast\_320 (Phase I)

- 309 Unique Structures
- Replicates for QC
- 291 Pesticide Actives
- 9 Industrial Chemicals
- 13 Parent/Metabolite pairs
- 56/73 Proposed Tier 1 Endocrine Disruption Screening Program
- 14 High Production Volume Chemicals
- 11 HPV Challenge



# ToxRefDB: EPA Pesticide DERs

**Toxicological Reference Database - Study Input Form**

**Data Entry Completeness Score**  
Partially Complete (Effect Data)

**Historic Study Identifiers**  
MRID#: 44858001  
Primary Study Year: 1999  
Supplemental MRID/History ID(s):

**Study/Data Quality**  
Data Usability: Acceptable Guideline (post-1998)  
Study-Level Comments: Note: Thyroid weights inc in male and dec in female. Thyroid neoplasia increase in male and decrease in female (both statistically significant).

**Test Material Information**  
Chemical: Imazali  
Purity (%): 97.4  
Lot/Batch#: ZR023979G3F661  
Source: ZR023979G3F661 / >97.4% a.i. / ZR023979G3G641 / >98.6% a.i.

**Animal and Dose Information**  
Species: rat  
Method/Route of Administration:   
Dose: 10.8 mg/kg/day  
Duration: 104 week  
N: 50

**Study Effect List**

Adult (P1)	Gender	Initial-to-Terminal	Dose	Duration	N
Adult (P1)	M	Initial-to-Terminal	10.8 mg/kg/day	104 week	50
Adult (P1)	F	Initial-to-Terminal	14.6 mg/kg/day	104 week	50
Adult (P1)	M	Initial-to-Terminal	65.8 mg/kg/day	104 week	50
Adult (P1)	F	Initial-to-Terminal	85.2 mg/kg/day	104 week	50
Adult (P1)	M	Initial-to-Terminal	134.8 mg/kg/day	104 week	50
Adult (P1)	F	Initial-to-Terminal	168.8 mg/kg/day	104 week	50

**EFFECT DATA**  
Click on "View or Add Critical Effect Data by Type" to input effect data for any treatment group by effect type.


**Study Design Level Controls**  
Records: 1

- Computable toxicity resource
- Retrospective data analysis
- Endpoints for modeling
- Reference tox data for ToxCast

- 2073 Studies for 480 Chemicals
- Rat, Mouse, Rabbit
- Chronic, Repro, Developmental


Study Design

Treatment Groups




<http://www.epa.gov/ncct/toxrefdb/>

# >\$1B *In Vivo* Chronic/Cancer Bioassay Effects and Endpoints



# Initial Chronic Rat & Mouse Endpoints for Predictive Modeling



# ToxCast *In vitro* HTS Assays

## Biochemical Assays

- **Protein families**
  - GPCR
  - NR
  - Kinase
  - Phosphatase
  - Protease
  - Other enzyme
  - Ion channel
  - Transporter
- **Assay formats**
  - Radioligand binding
  - Enzyme activity
  - Co-activator recruitment


467 Endpoints

## Cellular Assays


- **Cell lines**
  - HepG2 human hepatoblastoma
  - A549 human lung carcinoma
  - HEK 293 human embryonic kidney
- **Primary cells**
  - Human endothelial cells
  - Human monocytes
  - Human keratinocytes
  - Human fibroblasts
  - Human proximal tubule kidney cells
  - Human small airway epithelial cells
- **Biotransformation competent cells**
  - Primary rat hepatocytes
  - Primary human hepatocytes
- **Assay formats**
  - Cytotoxicity
  - Reporter gene
  - Gene expression
  - Biomarker production
  - High-content imaging for cellular phenotype

# ToxCast\_320 Phase I Chemicals


## ToxCast Phase I HTS (467 assays)




# Multiple Assays per Endpoint




# ToxCast Predictive Modeling of Chronic Rat Liver Apoptosis/Necrosis



# Rat Liver Tumorigens are diverse in chemical structure and *in vitro* Signature



# Structure Class vs Bioactivity Class




## Chemical structure class:


- Cluster according to activity and mechanism
- Differences in activity profiles can discriminate within structure class

## Bioactivity profile class:


- Can project onto multiple chemical classes
- Potentially broader coverage of chemical space
- Implies mechanistic similarity



# ToxCast: High-Multi-Dimensional Data



# ToxCast: Data Publication & Exploration




# ToxCast™ Data Analysis Summit, May 14-15, 2009



U.S. ENVIRONMENTAL PROTECTION AGENCY



## National Center for Computational Toxicology



[Contact Us](#)

Search:

☐ All EPA ☒ This Area

Go

You are here: [EPA Home](#) » [National Center for Computational Toxicology](#) » [ToxCast™ Program](#)  
» [ToxCast™ News](#)

Home

Basic Information

Organization  
Post Doc Profiles

Framework

Research Activities

ACToR  
DSSTox  
ExpoCast™  
ToxCast™  
ToxRefDB  
v-Liver™  
v-Embryo™

Conferences and  
Seminars

Products

Journal A  
Book Cha  
Presentat

BOSC Inform

EPA Commu

## ToxCast™ Program

Predicting Hazard, Characterizing Toxicity Pathways, and Prioritizing  
the Toxicity Testing of Environmental Chemicals

## ToxCast™ Data Analysis Summit

Transforming Toxicity Testing From In Vivo to In Vitro:  
A Computational Toxicology Challenge

*The First ToxCast™ Data Analysis Summit*  
Hosted by U.S. EPA's National Center for Computational  
Toxicology  
EPA Campus, Research Triangle Park NC

### ToxCast™ Navigation

[Introduction](#)  
[Chemicals](#)  
[Assays](#)  
[Information Management](#)  
[Partnerships](#)  
[Contractors](#)  
[Presentations](#)

- Pre-release of Phase 1 ToxCast data to analysis partners
- Over 200 registered attendees, 60 presenters
- Wide range of statistical, machine learning approaches
- Wide variety of prediction schemes (HTS+SAR)

# ToxCast™ Data Analysis Summit, May 14-15, 2009



## *Impressions, Conclusions, Lessons...*

- Global associations (*in vitro* to *in vivo*) not apparent  
→ *local models possible chemical feature/biology space*
- Statistical approaches for highly sparse, unbalanced data needed  
→ *new methods proposed*
- Chemical descriptors alone better than HTS alone  
→ *HTS+chemical descriptors give best QSAR models*
- Existing SAR carcinogenicity prediction models (LAZAR, ToxTree, PASS) built on public data performed poorly  
→ *point to lack of coverage of non-genotoxic mechanisms*
- Public data availability and transparency successful in engaging wide range of researchers and capabilities in analysis



### **New Structural Alerts for Carcinogenicity Derived from a Pesticide Data Set**


Susanne A. Stalford, Carol A. Marchant and Richard V. Williams  
Lhasa Limited, 22-23 Blenheim Terrace, Woodhouse Lane, Leeds LS2 9HD, UK  
[susanne.stalford@lhasalimited.org](mailto:susanne.stalford@lhasalimited.org)

# ToxCast Data Landscape: Implications for Genetox

- 309 ToxCast Phase I chemicals
  - *Mostly pesticides*
  - *Unique chemical space*
- High proportion of non-genotoxic carcinogens
- No genetox data provided

SAL data collected from public sources for approx 108 ToxCast chemicals to assess genetox-related assays \*

Principal Components Projection




*Knight et. al, Reg Tox Pharmacol, 2009, 55:188-199.*

# ToxCast/Tox21: Genetox Assays


- GreenScreen HC GADD45 $\alpha$ -GFP Reporter Assay (p53 competent) (*Gentronix, Ltd.*)
- CellCiphr p53 (*Cellumen Inc.*)
- CellSensor p53RE-bla (*Invitrogen Corp., provided by NCGC*)

Phase I Chemicals x Assays



*Knight et. al, Reg Tox Pharmacol, 2009, 55:188-199.*

# A rodent bioassay vs. an HTS genetox assay




*Knight et. al, Reg Tox Pharmacol, 2009, 55:188-199.*

*Slide results courtesy of Chihae Yang, FDA CFSAN, ToxCast Data Analysis Summit, May 2009*



# Tox21 Collaboration



Natio  
Enviro  
L

- Combined HTS plates (7x1408) high interest chemicals
- Joint assay development
- NTP Analytical QC
- Use of NCGC HTS testing capabilities
- EPA informatics (ACToR/DSSTox)
- *FDA preclinical toxicity data*




**U.S. Food and Drug Administration**  
Protecting and Promoting Your Health

CFSAN / CDER




NIH CHEMICAL GENOMICS CENTER



Office of Research and Development  
National Center for Computational Toxicology

Toxicology Project Team 22


# ToxCast/Tox21 Testing Landscape



# ToxCast Phase II

- Add approx 700 new chemicals to 309 Phase I set
- Pfizer: ~ 100 failed drugs with pre-clinical/clinical tox data
- Glaxo: liver toxicity data for approx 150 drugs
- L'Oreal: sponsoring 10 chemicals for Phase II
- FDA CFSAN/CDER data rich chemicals to be included
- Model organisms: *c. elegans* (NTP), whole embryo zebrafish (EPA)
- Expanded toxicity data models and databases to include:
  - *Developmental Neurotox, Immunotox, Genetox*

# ToxCast/Tox21 Testing Landscape



# Challenges for Tox21/ToxCast

## Assays

- ❖ Reproducibility
- ❖ Sensitivity
- ❖ Biological relevance

- ✓ Plate replicates
- ✓ Dose response
- ✓ Assay replicates
- ✓ Positive controls

## Chemicals

- ❖ Purity, Identity
- ❖ Stability
- ❖ Solubility
- ❖ Accuracy of representation

- ✓ Chemical filters & selection process
- ✓ Analytical QC
- ✓ Structure QC

## Metabolism, ADME

- ❖ Many assays do not have metabolic capability
- ❖ ADME missing in *in vitro*

- ✓ Assays with metabolic capability
- ✓ Include known metabolites
- ✓ Active metabolite features represented
- ✓ Metabolic prediction models

# ToxCast/Tox21: GeneTox

- Available HTS GeneTox tests under consideration:
  - GreenScreen Human Cell Assay (GADD45α –GFP reporter)  $\pm$ S9
  - Ames II assay
  - *In vitro* Micronucleus assay
  - *In vitro* Comet assay
  - *In vitro* Caspase 3/7 Cytotoxicity assay
- ToxRefDB Genetox data from DERs for pesticides
- ToxML efforts to capture Genetox data for public and FDA chemicals
- Availability of hundreds of chemicals having rich profile of both in vivo chronic (cancer) data & genetox data
  - EPA, NTP, FDA CFSAN, FDA CDER

# SAR - SAL Mutagenicity Prediction

*Hansen et al (2009) JCI, 49:2077-2081*

- Created large public Benchmark dataset of SAL results:

- 6512 compounds (3503 positive, 3009 negative)
- Conflicting results removed, est. 10-15% experimental error

- ▶ On large diverse set of >6000 chemicals, SAR methods reliably predict correct SAL outcome 86% of the time

- ▶ Experimental reproducibility of SAL experiment estimated between at 85-90%

*What regions of chemical space are best predicted? Most poorly predicted?*

perform worse than machine learning methods

# Questions for Genetox Screening

- What endpoint are of most interest?
  - Genetox or cancer?
  - In rodents or humans?
- Is SAL mutagenicity the best target for modeling?
- Are SAR models for SAL mutagenicity good enough?
  - In some areas of chemical (MOA) space, perhaps yes
  - In other areas of chemical space, may need to augment with HTS results
- Can we make better use of SAR & HTS tailored to regions of chemical feature/mechanism space?

# New Approaches to Toxicity Screening

- ✓ Use broad chemistry space (features) to probe biological space
- ✓ Heavy reliance on new informatics approaches
- ✓ Many sources of error – recognize & minimize
- ✓ Large-scale profiling generates patterns, includes redundancy to manage “noise”
- ✓ Screening is NOT targeted testing
- ✓ New data, new possibilities

# Acknowledgements:

## ✦ EPA NCCT ToxCast Team:

Robert Kavlock (Director, NCCT)  
David Dix (ToxRefDB, HTS, Genomics)  
Keith Houck (HTS)  
Matt Martin (ToxRefDB)  
Richard Judson (ACToR, ToxMiner)  
Thomas Knudsen (ToxRefDB, v-Embryo)  
David Reif (ToxMiner)  
Stephen Little (Genetox)

## ✦ EPA NCCT DSSTox Team:

Maritja Wolf, Tom Transue – Lockheed Martin, Contractors to the US EPA

## ✦ External Collaborators:

Chihae Yang, FDA/CFSAN  
Alex Tropsha, UNC-Chapel Hill  
Andrew Knight & colleagues, Gentronix Ltd.  
Chris Austin & colleagues, NCGC/NIH  
Ray Tice & colleagues, NTP/NIEHS

*This work was reviewed by EPA and approved for publication but does not necessarily reflect official Agency policy.*